India battles fatal fungal threat as COVID-19 deaths near 300,000
Doctors in India are fighting a fatal fungal infection affecting COVID-19 patients or those who have recovered from the disease amid a coronavirus surge that has driven the country’s fatalities to nearly 300,000.
The life-threatening condition, known as mucormycosis, is relatively rare, but doctors suspect the sudden increase in the infection could further complicate India’s fight against the pandemic.
India has reported more than 26 million confirmed cases of the coronavirus since the pandemic began, with almost half occurring in the past two months. On Sunday, the Health Ministry reported 3,741 new deaths, driving India’s confirmed fatalities to 299,266. (The United States, with less than one-fourth the population of India, has had roughly double the number of confirmed fatalities since the pandemic began.)
India also reported 240,842 new infections, as daily cases remained below 300,000 for a week. The numbers are almost certainly undercounts, with many cases likely being missed due to limited testing.
Experts say new infections in India, which had been rising steeply, may finally be slowing. But there are some early indications that mucormycosis, also known as “black fungus,” is fast becoming a cause of worry.
Some scientists say India’s COVID-19 surge this spring has less to do with a variant and more to do with the government’s lifting of pandemic rules.
Mucormycosis is caused by exposure to mucor mold, which is commonly found in soil, air and even in the nose and mucus of humans. It spreads through the respiratory tract and erodes facial structures. Sometimes, doctors have to surgically remove the eye to stop the infection from reaching the brain.
On Saturday, federal minister Sadananda Gowda said nearly 9,000 cases had been reported in India so far, leading to a shortage of Amphotericin B, the drug used to treat the condition.
Gowda didn’t share the number of fatalities, but local media have said more than 250 have died because of the disease.
Health officials were working to alleviate the drug shortage, which comes at a time when the country is already short on supplies of oxygen and other healthcare needs, Gowda said.
Mucormycosis has a high mortality rate, and was already present in India before the pandemic. It is not contagious, but its frequency in the last month has left doctors shocked.
“It is a new challenge, and things are looking bleak,” said Ambrish Mithal, the chairman and head of the endocrinology and diabetes department at Max Healthcare, a chain of private hospitals in India.
Mithal says the fungal infection preys on patients with weakened immune systems and underlying conditions, particularly diabetes, and those using steroids. Uncontrolled blood sugar can put immunocompromised people at a higher risk of contracting the disease.
“Earlier, I used to come across just a few cases every year,” Mithal said, “but the current infection rate is frightening.”
Many Indian Americans in California are straddling two worlds: an improving COVID outlook in the U.S. and a heartbreaking crisis in India.
The latest surge of coronavirus infections in rural India has already taken a toll. Now heath experts are worried that over-the-counter medication, including steroids, can increase the prevalence of mucormycosis.
S.K. Pandey, a medical officer at Ram Manohar Lohia Hospital in Uttar Pradesh state’s Lucknow city, said unqualified doctors were giving steroids to patients in many rural areas without giving a thought to whether they required the drug.
“This has led to an increase in black fungus cases in smaller cities where the patient has not even been hospitalized,” he said.
India’s Health Ministry on Thursday asked states to track the spread of the condition and declare it an epidemic, making it mandatory for all medical facilities to report the cases to a federal surveillance network.
Prime Minister Narendra Modi on Friday called the disease a “new challenge.”
Start your day right
Sign up for Essential California for news, features and recommendations from the L.A. Times and beyond in your inbox six days a week.
You may occasionally receive promotional content from the Los Angeles Times.
